Evidence map›Paper›PMID 32860299›Full record

ArticleCancer science2020

Prognostic impact of CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma: A multiinstitutional retrospective study.

Yoshihide Okumura, Satsuki Nakano, Takayuki Murase, Kaori Ueda, Daisuke Kawakita, Toshitaka Nagao, Kimihide Kusafuka, Makoto Urano, Hidetaka Yamamoto, Satoshi Kano and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Contemporary Management of Malignancies of the Parotid Gland: A State-of-the-Art Review.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026
    Review
  4. Article
  5. Article
  6. Unilocular cystic mucoepidermoid carcinoma: 6 cases reported and literature review.International journal of clinical and experimental pathology · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Cancer stem cells in head and neck cancer.American journal of stem cells · 2021
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 1 country.

Yoshihide OkumuraDepartment of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Satsuki NakanoDepartment of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Takayuki MuraseDepartment of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Kaori UedaDepartment of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Daisuke KawakitaDepartment of Otolaryngology, Head and Neck Surgery, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Toshitaka NagaoDepartment of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.
Kimihide KusafukaDepartment of Pathology, Shizuoka General Hospital, Shizuoka, Japan.
Makoto UranoDepartment of Diagnostic Pathology, School of Medicine, Fujita Health University, Toyoake, Japan.
Hidetaka YamamotoDepartment of Anatomic Pathology, Graduate of School of Medical Science, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-9148-6445
Satoshi KanoDepartment of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Kiyoaki TsukaharaDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Kenji OkamiDepartment of Otolaryngology-Head and Neck Surgery, Tokai University School of Medicine, Isehara, Japan.
Toru NagaoDepartment of Maxillofacial Surgery, School of Dentistry, Aichi-Gakuin University, Nagoya, Japan.
Nobuhiro HanaiDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Hiroshi IwaiDepartment of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Hirakata, Japan.
Ryo KawataDepartment of Otorhinolaryngology-Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan.
Yuichiro TadaDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, Tokyo, Japan.
Ken-Ichi NibuDepartment of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Hiroshi InagakiDepartment of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.ORCID https://orcid.org/0000-0001-6157-636X
Nagoya City University · JPTokyo Medical University · JPAichi Gakuin University · JPAichi Cancer Center · JPFujita Health University · JPHokkaido University · JPKansai Medical University · JPKobe University · JPKyushu University · JPMita Hospital · JPOsaka Medical and Pharmaceutical University · JPShizuoka General Hospital · JPTokai University · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology 15K08351Ministry of Education, Culture, Sports, Science and Technology 17K08746
6 · The paper itself

Abstract

Mucoepidermoid carcinoma (MEC) is rare, but the most common primary malignancy of the salivary gland and not infrequent in young individuals. CRTC1/3-MAML2 fusions are frequently detected in MEC and are useful as a diagnostic biomarker. However, there has been debate as to whether the fusions have prognostic significance. In this study, we retrospectively collected 153 salivary gland MEC cases from 11 tertiary hospitals in Japan. As inclusion criteria, the MEC patients in this study had curative surgery as the initial treatment, received no preoperative treatment, and had no distant metastasis at the time of the initial surgery. The MEC diagnosis was validated by a central pathology review by five expert salivary gland pathologists. The CRTC1/3-MAML2 fusions were detected using FISH and RT-PCR. In 153 MEC cases, 90 (58.8%) were positive for CRTC1/3-MAML2 fusions. During the follow-up period, 28 (18.3%) patients showed tumor recurrence and 12 (7.8%) patients died. The presence of the fusions was associated with favorable tumor features. Of note, none of the fusion-positive patients died during the follow-up period. Statistical analysis showed that the presence of the fusions was a prognostic indicator of a better overall survival in the total and advanced-stage MEC cohorts, but not in the early-stage MEC cohort. In conclusion, CRTC1/3-MAML2 fusions are an excellent biomarker for favorable overall survival of patients with salivary gland MEC.

Indexed as

AdultAgedBiomarkers, TumorCarcinoma, MucoepidermoidFemaleHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedNeoplasm GradingNeoplasm StagingOncogene Proteins, FusionPrognosisRetrospective StudiesSalivary Gland NeoplasmsTrans-ActivatorsBiomarkers, TumorCRTC1 protein, humanCRTC3 protein, humanMAML2 protein, humanOncogene Proteins, FusionTrans-ActivatorsTranscription FactorsCRTC1/3-MAML2mucoepidermoid carcinomaNCCN Guidelinessalivary glandsurvival analysis

Identifiers

PMID32860299
PMCPMC7648036
OpenAlexW3082597509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.